Moximed Valuation, Funding & Investors
Moximed is valued at $63M as of January 2016.
Last Moximed valuation
$63M
Series B · Jan 2016
Last Moximed funding round
$61M
Series D · Aug 2024
Cumulative funding Moximed raised
$197M
across 5 funding rounds
Key investors in Moximed
New Enterprise Associates
Gilde Healthcare
GBS Ventures
Morgenthaler Ventures
Vertex Ventures
Future Fund
About Moximed
Moximed manufactures the MISHA Knee System, a minimally invasive shock absorber implant for medial compartment knee osteoarthritis. This outpatient procedure preserves natural knee anatomy for patients unsuitable for total knee arthroplasty. Clinical trials demonstrate reduced pain and improved function for up to five years post-implantation. The FDA-cleared device targets active adults aged 40 to 65. Moximed, headquartered in Sunnyvale, California, collaborates with orthopedic surgeons across the United States and Europe.
Founded
2006
HQ
San Francisco, CAWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$63M (Jan 2016)
Sectors
Moximed Valuation
Moximed is currently valued at $63M, based on its Series B in January 2016.
The $13M round was led by New Enterprise Associates, with participation from GBS Ventures and Gilde Healthcare.
Moximed's valuation has moved from $83M at its Series B in May 2015 to $63M in January 2016, across 2 priced rounds.
Moximed valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jan 2016 | Series B | $63M |
| May 2015 | Series B | $83M |
Moximed Funding History
Moximed has raised a total of $197M across 5 funding rounds.
Moximed's first fundraising round was a $33M Series B in May 2015. The most recent completed round was a $61M Series D in August 2024.
Moximed funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Aug 2024 | Series D | Elevage Medical Technologies (lead); GBS Ventures; Warren Point Capital; Vertex Ventures HC; New Enterprise Associates; Advent Life Sciences; Gilde Healthcare; Future Fund; Morgenthaler Ventures; Cormorant Asset Management | $61M | - | Moximed is a US-based medical device company developing the MISHA Knee System, an implantable shock absorber designed to treat medial compartment knee osteoarthritis (OA) in pre-arthroplasty patients, addressing pain and function loss without full knee replacement. The technology stems from over a decade of clinical research and aims to elevate the standard of care for millions affected by knee OA. On August 13, 2024, Moximed closed $61 million in Series D preferred stock financing, led by new investor Elevage Medical Technologies (a Patient Square Capital platform), with an option for up to an additional $30 million, bringing the total potential to $91 million. New investors Cormorant Asset Management and Warren Point Capital joined, alongside existing investors including New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Gilde Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler Ventures. As part of the deal, Michael Wasserman from Elevage Medical joined Moximed's Board of Directors. The proceeds will fuel US commercialization of the MISHA Knee System, including expansion of commercial infrastructure to meet surgeon and patient demand in the growing knee OA market. Executives highlighted the financing as validation of the product's market opportunity, differentiation, and clinical value in a competitive environment, with strong interest from surgeons and patients already generating commercial momentum. Moximed has now raised approximately $257.5 million across 11 rounds, with prior funding including Series C-II in 2022. The company is positioned to scale access to its breakthrough technology amid a large addressable market for OA treatments. |
| Aug 2022 | Series C | Advent Life Sciences (lead); GBS Ventures; Vertex Ventures; New Enterprise Associates; Gilde Healthcare; Future Fund; Morgenthaler Ventures | $40M | - | Moximed is a Fremont, California-based medical device company developing the MISHA Knee System, the world's first implantable shock absorber for medial compartment knee osteoarthritis (OA), designed to reduce pain, improve function, and delay total knee replacement. In August 2022, Moximed announced $40 million in Series C equity and debt financing led by Advent Life Sciences, with participation from returning investors New Enterprise Associates (NEA), Future Fund, Vertex Ventures HC, Gilde Healthcare, GBS Venture Partners, and Morgenthaler Ventures, plus debt from Runway Growth Capital. The funds support pursuit of FDA approval, anticipated by 2023, clinical studies, surgeon and payer education, and commercialization infrastructure. Prior rounds included $50 million Series C in 2017 and $33 million in 2015. A study by Moximed, set for publication in September 2022, demonstrated the MISHA system's ability to reduce pain, improve function, and potentially delay knee replacements, with CEO Anton Clifford describing results as better than expected. The device targets working patients with knee OA needing options between conservative care and joint replacement, aiming to alter the treatment paradigm for millions. Subsequently, Moximed closed a $91 million Series D in August 2024 led by Elevage Medical Technologies ($61 million preferred stock with $30 million option), joined by Cormorant Asset Management, Warren Point Capital, and existing investors including Advent Life Sciences. This funding accelerates commercialization amid surgeon and patient interest post-FDA progress. |
| Mar 2017 | Series C | Advent Life Sciences (lead); Future Fund (lead); GBS Ventures; Vertex Ventures; New Enterprise Associates; Gilde Healthcare; Morgenthaler Ventures | $50M | - | Moximed, Inc. develops unicompartmental load absorber implants, such as the KineSpring System and Atlas System, for active patients with painful knee osteoarthritis (OA). These shock-absorbing implants aim to reduce joint load without requiring bone cutting or removal, preserving natural joint anatomy. The company created the category of shock-absorbing implants for knee OA, with durability demonstrated to nearly nine years in initial patients. At the time, the Atlas System was CE Marked in Europe and available at select centers, while investigational in the US. On March 16, 2017, Moximed closed an oversubscribed Series C financing round of $50 million. New investors Advent Life Sciences and Future Fund joined existing backers New Enterprise Associates (NEA), Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, and Vertex Ventures (also referred to as Vertex Healthcare). Advent Life Sciences and Future Fund were noted as lead investors. As part of the round, Shahzad Malik from Advent Life Sciences and Brigitte Smith from GBS Venture Partners joined the board. The funding was intended to support FDA approval and early US commercialization of Moximed's products. The timing aligned with completion of primary endpoint follow-up for the FDA pivotal study of the KineSpring System and ongoing enrollment in the FDA IDE study for the Atlas System. CEO Kevin Sidow highlighted strong patient interest and surgeon enthusiasm in the Atlas study, targeting patients aged 35-65 who seek alternatives to knee replacement. Moximed addresses a growing segment of knee OA patients desiring to maintain active lifestyles. Investors viewed the opportunity as significant for innovative treatments in medtech, particularly orthopedics. |
| Jan 2016 | Series B | New Enterprise Associates (lead); GBS Ventures; Gilde Healthcare | $13M | $63M | - |
| May 2015 | Series B | GBS Ventures; Vertex Ventures; Vertex Ventures HC; New Enterprise Associates; Gilde Healthcare; Morgenthaler Ventures | $33M | $83M | Moximed, Inc., based in Hayward, California, develops the KineSpring System, a minimally invasive joint unloading knee implant designed for pre-arthroplasty patients with knee osteoarthritis to reduce pain, preserve joint anatomy, and delay or avoid total knee replacement. The device, CE marked since 2009, is available in major European markets with over 1,000 implants worldwide as of May 2015, and remains investigational in the U.S., pursuing FDA approval via the Soar IDE trial. In May 2015, Moximed closed approximately $33 million in financing, described variably as a Series B round or additional private equity, led by new investor Vertex Venture Holdings Ltd. (with Christopher Shen joining the board) and returning investors New Enterprise Associates, Gilde Healthcare Partners, Morgenthaler Ventures, and GBS Venture Partners. Prior total funding raised was reported as $105 million including this round or $80.6 million to date by some sources. The proceeds support FDA approval efforts for the KineSpring System and expansion of commercial sales in Europe. CEO Kevin Sidow highlighted the encouragement from patient outcomes and investor support, positioning joint unloading as a potential standard of care to benefit patients, surgeons, payers, and employers by avoiding costly revisions. The company, founded in 2006 by co-founder Anton Clifford, targets active lifestyle patients unresponsive to conservative therapies like pain meds and bracing but not yet ready for arthroplasty. |
Who has invested in Moximed?
11 investors have backed Moximed across its funding rounds, including New Enterprise Associates, Gilde Healthcare, GBS Ventures, Morgenthaler Ventures, Vertex Ventures and Future Fund.
Lead investors include Elevage Medical Technologies, Advent Life Sciences, Future Fund and New Enterprise Associates.
Moximed Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
 Melbourne | 5 | Participant | May 2015 | |
| San Francisco, CA | 5 | Lead | May 2015 | |
 Netherlands | 5 | Participant | May 2015 | |
| San Francisco, CA | 4 | Participant | May 2015 | |
 Singapore | 3 | Participant | May 2015 | |
 London | 3 | Lead | Mar 2017 | |
| Melbourne | 3 | Lead | Mar 2017 | |
| San Francisco, CA | 2 | Participant | May 2015 | |
| Santa Barbara, CA | 1 | Participant | Aug 2024 | |
This data is available for Pro users. Sign up to see all 11 Moximed investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialMoximed Competitors
Moximed competitors include listed companies like K Pharma and Pangaea Oncology, and private ones like Shenzhen Superline Technology Co., Ltd., Limbic, Shanghai Horizon Medical Technology and Intelligent Haptronic Solutions.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 Shenzhen | Private | - | - | $63M | - | |
| London | Private | - | - | $62M | - | |
| Shanghai | Private | - | - | $62M | - | |
 Vancouver | Private | - | - | $61M | - | |
 Japan | Publicly listed | - | ($6M) | $60M | - | |
 Spain | Publicly listed | $17M | ($1M) | $59M | 3.7x |
Moximed Public Comps
Moximed is still privately-owned, but its public comps include Zepp Health, K Pharma, Pangaea Oncology, Outset Medical, TELA Bio, QTREX Quantum, Osang Healthcare, Daxor, Medicalgorithmics and Agfa-Gevaert.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $259M | ($27M) | 0.9x | 0.8x | (9.0x) | (29.3x) | |||
| - | ($6M) | - | - | (8.7x) | - | |||
| $17M | ($1M) | 3.8x | 3.7x | (58.0x) | (19.8x) | |||
| $119M | ($70M) | 0.1x | 0.1x | (0.2x) | (0.3x) | |||
| $80M | ($32M) | 1.1x | 1.1x | (2.6x) | (2.8x) | |||
| $289K | ($13M) | 191.5x | 191.5x | (4.3x) | (5.2x) | |||
| $94M | $8M | 0.7x | - | 8.6x | - | |||
| $10M | - | 6.6x | 7.9x | - | - | |||
This data is available for Pro users. Sign up to see all Moximed competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Moximed
| When was Moximed founded? | Moximed was founded in 2006. |
| Where is Moximed headquartered? | Moximed is headquartered in San Francisco, CA, United States. |
| Is Moximed publicly listed? | No, Moximed is a private, VC-backed company. |
| What is Moximed's valuation? | Moximed was last valued at $63M in its Series B in January 2016. |
| How much funding has Moximed raised? | Moximed has raised $197M across 5 funding rounds. |
| What was Moximed's last funding round? | Moximed's last funding round was a $61M Series D in August 2024, led by Elevage Medical Technologies. |
| Who are Moximed's investors? | Moximed's investors include GBS Ventures, New Enterprise Associates, Gilde Healthcare, Morgenthaler Ventures, Vertex Ventures, Advent Life Sciences, Future Fund, Vertex Ventures HC, Warren Point Capital, Cormorant Asset Management and 1 other. |
| Which companies are comparable to Moximed? | Companies comparable to Moximed include Shenzhen Superline Technology Co., Ltd., Limbic, Shanghai Horizon Medical Technology, Intelligent Haptronic Solutions, K Pharma and Pangaea Oncology. |
See companies similar to Moximed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.